HONG KONG, Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2.0 + ADC2.0 therapeutic matrix, and continued orderly development of bispecific antibodies in major chronic disease areas, including autoimmune, respiratory, and central nervous system (CNS) disorders

Commercialization Reaches Record High

Commercial sales revenue for the first half of 2026 reached approximately RMB 1,803.2 million, representing a 28.7% increase year-over-year. As of the reporting date, the Company's total cash and cash equivalents, together with other short-term financial assets, stood at RMB 9,160.0 million.

By the end of 2025, all 12 indications across the Company's five self-commercialized innovative drugs had been included in China's National Reimbursement Drug List (NRDL). These include two non-small cell lung cancer (NSCLC) indications for ivonescimab (PD-1/VEGF bispecific antibody) and three cervical and gastric cancer indications for cadonilimab (PD-1/CTLA-4 bispecific antibody). NRDL inclusion has significantly expanded market coverage and patient access.

In August 2026, the National Medical Products Administration (NMPA) approved ivonescimab in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC), providing a new growth driver for commercialization.

Since the beginning of 2026, the Company has continued to strengthen its commercialization capabilities, with steady progress in market access, coverage, and penetration. These efforts lay a solid foundation for the sustained release of innovative drug value in the second half of the year and beyond.

IO2.0 Global Strategy Advances

Following the approvals of ivonescimab and cadonilimab - two first-in-class immuno-oncology (IO) cornerstone therapies - Akeso has continued to advance the Company's global IO2.0+ strategy. The Company is building a bispecific antibody-based IO therapeutic matrix designed to treat multiple tumor types through combining different types of therapy.

Biliary tract cancer: In August 2026, the Phase III clinical study of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy for the first-line treatment of advanced biliary tract cancer met its primary endpoint of overall survival (OS), demonstrating clinically meaningful and statistically significant OS benefit. This regimen represents a major advancement in first-line treatment of biliary tract cancer.

Squamous NSCLC: In August 2026, ivonescimab plus chemotherapy received NMPA approval for first-line treatment of sq-NSCLC. Based on the HARMONi-6 study, this is the first regimen to achieve dual positive OS and progression-free survival (PFS) results versus a PD-1 monoclonal antibody plus chemotherapy in a randomized, double-blind Phase III trial. Ivonescimab combination therapy marks a significant advance in first-line sq-NSCLC treatment.

EGFR-TKI-resistant NSCLC: In July 2026, an updated analysis of the global multicenter Phase III HARMONi study demonstrated continued OS improvement (HR = 0.76). The OS hazard ratio in Western patients was also 0.76, highly consistent with the China-conducted HARMONi-A study (HR = 0.74, P = 0.02). The Biologics License Application (BLA) for this indication is currently under review by the U.S. Food and Drug Administration (FDA). The HARMONi-A study is the first immuno-oncology trial globally to achieve dual positive OS and PFS results with both clinical benefit and statistical significance in this setting. Ivonescimab combination therapy represents a major advancement in the treatment of EGFR-TKI-resistant non-squamous NSCLC.

PD-L1-positive NSCLC: In the HARMONi-2 study, ivonescimab became the first therapy globally to demonstrate positive results versus pembrolizumab in a Phase III trial, establishing a new benchmark in first-line treatment of PD-L1-positive NSCLC.

Cadonilimab: Cadonilimab continues to advance across multiple indications, including gastric cancer and hepatocellular carcinoma (HCC). Key programs include an international multicenter Phase III study of cadonilimab plus chemotherapy versus nivolumab plus chemotherapy for first-line treatment of gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, a perioperative Phase II study in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), and an international multicenter registrational study of cadonilimab plus lenvatinib in HCC patients who progressed after prior atezolizumab plus bevacizumab.

As cornerstone agents of global IO2.0, ivonescimab and cadonilimab are establishing a combination therapy ecosystem through novel mechanisms, with the potential to elevate the standard of care across multiple tumor types. Ivonescimab is currently being evaluated in combination trials with Revolution Medicines' RAS(ON) inhibitor, ARCUS Biosciences' HIF-2α inhibitor, Virogin Biotech's VG201 oncolytic virus, and TransThera Biosciences' tinengotinib, spanning NSCLC, pancreatic cancer, colorectal cancer, clear cell renal cell carcinoma, and hepatocellular carcinoma. Cadonilimab is advancing multi-pathway combination strategies, including combinations with small molecules such as axitinib and tinengotinib in renal and liver cancers, as well as collaborations with the Dana-Farber Cancer Institute and Mass General Brigham to evaluate cadonilimab in combination with INOVIO's DNA medicine INO-5412 in glioblastoma (GBM).

Ivonescimab is currently being evaluated in more than 17 registrational Phase II/III studies, including seven global registrational trials and 8 studies that use standard-of-care regimens as active comparators. These programs encompass 8 registrational/Phase III studies in lung cancer, as well as first-line MSS/pMMR colorectal cancer, first-line PD-L1-positive head and neck squamous cell carcinoma (in combination with CD47 antibody versus pembrolizumab), first-line biliary tract cancer (versus a durvalumab-based regimen), first-line triple-negative breast cancer, first-line pancreatic cancer, and first-line urothelial cancer (versus pembrolizumab plus a Nectin-4 ADC).

Cadonilimab is being evaluated in more than 13 registrational/Phase III clinical studies covering major cancer types, including gastric cancer, HCC, lung cancer, cervical cancer, pancreatic cancer, and esophageal squamous cell carcinoma. Two of these are international multicenter registrational studies.

IO2.0 + ADC2.0 Therapeutic Matrix

Akeso is the only company globally with two approved immuno-oncology bispecific antibodies and is actively exploring combination therapies of ivonescimab and cadonilimab with both proprietary and partnered antibody-drug conjugates (ADCs).

The Company has developed a series of next-generation ADCs designed to address the narrow therapeutic window associated with the safety limitations of existing ADC therapies. Among these, the innovative TROP2/Nectin-4 bispecific ADC AK146D1, next-generation HER3 ADC AK138D1, next-generation B7H3 ADC AK157D1, and bispecific ADC AK158D1 have successively entered clinical development.

Multiple Phase II studies evaluating AK146D1 in combination with ivonescimab in NSCLC, breast cancer, and urothelial cancer, as well as AK138D1 in combination with ivonescimab in lung and breast cancers, are underway, with a focus on first-line treatment of various solid tumors.

In parallel, ivonescimab has entered combination therapy collaborations with high-potential ADCs from domestic and international partners, including Pfizer, GSK, Biokin, and MediLink. These collaborations cover agents such as EGFR/HER3 bispecific ADC, TROP2/HER3 bispecific ADC, B7H3 ADC, FGFR2b ADC, TROP2 ADC, and Nectin-4 ADC across high-incidence malignancies.

Looking further ahead, the Company's frontier programs continue to push additional new therapies into the clinic. The global first-in-class trispecific antibody AK150 (ILT2/ILT4/CSF1R) has entered clinical development, with additional trispecific antibodies and T-cell engager (TCE) bispecific/multispecific candidates expected to enter the clinic in the next year.

Entering the Bispecific Era in Immunology, CNS, and Respiratory Diseases

In autoimmune, respiratory, and CNS diseases, Akeso is leveraging its expertise in bispecific and multispecific antibody development, with strategic momentum steadily building. A series of internally-developed novel candidates, including AK139, a bispecific antibody for Immunology & Inflammation that targets IL-4R and ST2, and AK152, a bispecific amyloid-beta + brain shuttle antibody for the treatment of Alzheimer's disease have entered or are preparing to enter clinical development. These programs form a complementary pipeline alongside the Company's already marketed non-oncology products: ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), gumokimab (IL-17), and manfidokimab (IL-4Rα).

AI-Empowered Future Innovation Competitiveness

Akeso has adopted the use of AI in its R&D efforts for the past few years. The Company is further expanding the implementation of AI in many new scientific directions and therapeutic platforms.

Developed on Akeso's AI-driven drug discovery platform, AK139, an IL-4Rα/ST2 bispecific antibody, has advanced into 7 Phase II trials across respiratory and autoimmune indications. AK150, an ILT2/ILT4/CSF1R trispecific antibody, is in Phase I development. AK154, a personalized mRNA cancer vaccine that leverages AI-powered selection of high-affinity immunogenic mutations to create precision oncology therapies. A Phase I study of AK154 as monotherapy or in combination with cadonilimab or ivonescimab as adjuvant therapy in pancreatic cancer is currently ongoing.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multispecific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

The three major US stock indices closed higher, with the Nasdaq gaining more than 1%, driven by an 8.7% surge in NVIDIA Corporation (NVDA.US) after strong earnings results.

This morning (28th), the HSI opened at 25,410, down 155 points or 0.61%; the HSTECH opened at 4,580, down 39 points or 0.85%; and the HSCEI opened at 8,425, down 64 points or 0.76%.

Among major techs, BABA-W (09988.HK) lost 2.08%; MEITUAN-W (03690.HK), JD-SW (09618.HK) and BIDU-SW (09888.HK) shed more than 1%; while TENCENT (00700.HK) lost 0.85%.

Among blue chips, OOIL (00316.HK) opened 5.5% lower after its 1H profit dropped nearly 24%; HAIER SMARTHOME (06690.HK) slid 3.55% after results; SMIC (00981.HK) rose 0.42% after its interim net profit spiked 1.1x; CHINA LIFE (02628.HK) added 0.82% after interim dividend jumped up 50%; INNOVENT BIO (01801.HK) dived 2.14% after Temasek reduced its stake to below 5%.

Several Chinese banks are set to announce results shortly. ABC (01288.HK) faded 1.36%; BANK OF CHINA (03988.HK) opened 0.45% lower; ICBC (01398.HK) opened down 1.01%; and BANKCOMM (03328.HK) opened down 1.66%.

Among individuals, BILIBILI-W (09626.HK) gained 1.77% after adjusted net profit for the previous quarter climbed 25%; SHIMAO GROUP (00813.HK) faced another winding-up petition, with shares opening 10.45% lower.
~

AASTOCKS Financial News
Website: www.aastocks.com

TIME magazine released its TIME100 AI 2026 list of the world's 100 most influential people in AI field, with BABA-W (09988.HK) CEO Eddie Wu included on the annual ranking.

Others on the list include SpaceX CEO Elon Musk, OpenAI co-founder Sam Altman, ByteDance CEO Liang Rubo, Amazon.com, Inc. (AMZN.US) founder Jeff Bezos, and Anthropic co-founders Dario Amodei and Daniela Amodei.

TIME magazine said Alibaba is transforming into a global pioneer in open-source AI, having committed at least USD53 billion this year to AI and cloud infrastructure investment, and set a target of achieving annualized AI revenue of USD4.4 billion by year-end.

The magazine quoted Eddie Wu as saying that the democratization of AI will further narrow the education gap and enable fairer and more reasonable allocation of medical resources, while continuing to unleash vitality across society.
~

AASTOCKS Financial News
Website: www.aastocks.com

Broad-based growth across consumer electronics, communications and data center, and automotive electronics, supported by targeted investment in AI infrastructure, intelligent vehicles and global delivery capacity

DONGGUAN, China, Aug. 28, 2026 /PRNewswire/ -- Luxshare Precision Industry Co., Ltd. ("Luxshare Precision" or the "Company") (SZSE: 002475; HKEX: 02475), a global provider of precision intelligent manufacturing solutions, today announced unaudited results for the six months ended June 30, 2026.

Revenue increased 40.2% year over year to RMB 174.50 billion, while net profit attributable to shareholders rose 18.0% to RMB 7.84 billion. Net profit attributable to shareholders excluding non-recurring gains and losses increased 6.5% to RMB 5.96 billion. Gross margin expanded by 17 basis points to 11.78%.

The margin improvement reflected operating leverage and a more diversified revenue mix, with faster growth in Communications and Data Center and Automotive Electronics, both of which carry gross margins above the Company average. Internal innovation, AI-enabled manufacturing efficiency and disciplined cost management also helped absorb pressure from foreign-exchange movements, higher input costs and investment in new businesses.

"Our first-half performance demonstrates the resilience of Luxshare Precision's diversified portfolio and global operating platform," said Wang Laichun, Chairwoman and General Manager of Luxshare Precision. "We are investing with discipline in areas supported by clear customer demand and defined technology roadmaps, particularly AI-enabled devices, AI infrastructure and intelligent vehicles. Our priorities remain execution, operating efficiency and sustainable value creation."

Strategic Investment and Financial Discipline

Research and development investment increased 43.1% to RMB 6.57 billion, primarily reflecting higher spending on engineering talent, tooling, materials and certification. More than half of the Company's R&D investment supported technology preparation for programs approaching commercialization.

Capital expenditures totaled RMB 10.27 billion, up RMB 742 million year over year, and were mainly directed toward overseas facility expansion, supporting infrastructure and new product lines. The Company prioritizes investments linked to customer programs, localized delivery and long-term manufacturing flexibility.

Inventory was RMB 50.37 billion at June 30, 2026, up 19.0% from year-end 2025, below the Company's 40.2% revenue growth. The increase primarily reflected business expansion and strategic material preparation for selected products.

First-half operating cash flow was an outflow of RMB 2.45 billion, mainly due to seasonal supplier payments and more than RMB 5 billion of strategic inventory preparation. Operating cash flow turned positive in the second quarter, reaching RMB 4.62 billion.

Foreign-exchange volatility resulted in approximately RMB 1.99 billion of losses on foreign-currency-denominated monetary assets and liabilities. Foreign-exchange risk management activities generated approximately RMB 1.30 billion in related gains. Under applicable accounting treatment, these gains were recorded as non-recurring items, while the corresponding losses remained within both disclosed net profit measures.

Growth Across Three Core Businesses

Consumer Electronics revenue increased 19.3% to RMB 122.48 billion. Luxshare Precision continued to deepen core customer relationships and strengthen its ODM and end-to-end product development capabilities. By integrating expertise across acoustics, optics, electrical systems, thermal management, magnetics and precision structures, the Company is extending its participation from components and modules to product definition, system development and volume manufacturing. Priority areas include AI PCs, smart wearables, AI glasses and intelligent acoustic products.

Communications and Data Center revenue increased 49.7% to RMB 16.61 billion. The Company is building an integrated AI infrastructure portfolio spanning high-speed copper interconnects, optical interconnects, thermal management and power management. Operational progress included volume production of 800G optical products, batch shipments of 1.6T DAC, ACC and AEC products, continued customer introductions for liquid-cooling solutions, and scaled production of DC-DC server power modules. Luxshare Precision is also advancing 224G and 448G copper technologies and next-generation optical architectures.

Automotive Electronics revenue increased 274.1% to RMB 32.39 billion, supported by organic growth, customer program ramps and Leoni's contribution. The Company continued to expand its portfolio across connectors, wiring harnesses, intelligent control systems, smart chassis technologies and powertrain solutions. High-speed connectors and rear-wheel steering products have entered mass production, while intelligent cockpit and advanced driver-assistance platforms are progressing across multiple vehicle programs. Leoni's integration continued to outperform expectations, strengthening global customer access, engineering resources and localized delivery capabilities.

Global Platform and Outlook

Luxshare Precision operates across five continents, 29 countries and more than 100 production sites. This network supports localized delivery, customer collaboration and supply chain resilience. The Company's vertically integrated platform spans precision components, functional modules and system-level products, supported by AI-enabled digital tools for quality management, predictive maintenance, production scheduling and standardized global execution.

For the remainder of 2026, Luxshare Precision will continue supporting consumer electronics product launches and ODM/JDM programs; accelerating commercialization across high-speed interconnects, optical products, liquid cooling and power management; and expanding automotive customer programs while capturing further benefits from the Leoni integration.

The Company will maintain disciplined capital allocation and continue investing in technology, manufacturing capacity and global delivery capabilities that support sustainable, high-quality growth.

About Luxshare Precision

Luxshare Precision Industry Co., Ltd. is a global provider of precision intelligent manufacturing solutions serving Consumer Electronics, Communications and Data Center, Automotive Electronics and other technology-driven industries. The Company supports customers from product definition and process development through new product introduction, volume manufacturing and global delivery.

消費電子、通信與數據中心、汽車電子業務實現全面增長；公司持續佈局AI基礎設施、智能汽車領域，增強全球交付能力

中國東莞2026年8月28日 /美通社/ -- 全球精密智能製造解決方案提供商立訊精密工業股份有限公司（「立訊精密」或「公司」，SZSE:002475；HKEX: 02475）今天公佈了截至2026年6月30日的六個月未經審計業績。

公司營收同比增長40.2%，達到1745.0億元人民幣；歸屬於股東的淨利潤同比增長18.0%，為78.4億元人民幣；扣除非經常性損益後歸屬於股東的淨利潤同比增長6.5%，達59.6億元人民幣。毛利率提升17個基點，至11.78%。

毛利率改善源於經營槓桿效應以及收入結構多元化：通信與數據中心、汽車電子業務增速加快，兩大板塊毛利率均高於公司整體平均水平。內部技術創新、人工智能(AI)助力生產效率提升以及審慎的成本管控，也幫助公司對沖了匯率波動、原材料成本上漲以及新業務投入帶來的經營壓力。

立訊精密董事長兼總經理王來春表示：「公司上半年業績，印證了立訊精密多元化業務佈局與全球化運營平台具備較強抗風險能力。我們圍繞客戶明確需求與清晰技術路線圖進行審慎投資，重點佈局AI終端設備、AI基礎設施與智能汽車賽道。公司依舊將業務落地執行、運營效率提升以及可持續價值創造作為工作重心。」

戰略投資與財務管控

研發投入增長43.1%，達65.7億元人民幣，主要用於工程技術人才擴充、工裝模具、物料以及認證相關支出。公司超過半數研發資金用於即將實現商業化落地項目的技術儲備。

資本開支合計102.7億元人民幣，同比增加7.42億元，主要投向海外廠區擴建、配套基礎設施建設以及新產品產線佈局。公司投資優先匹配客戶項目需求、本地化交付以及長期製造柔性能力建設。

截至2026年6月30日，公司存貨規模503.7億元人民幣，較2025年年末增長19.0%，增幅低於公司40.2%的營收增速。存貨增長主要來自業務規模擴張以及部分產品戰略性物料儲備。

上半年經營現金流淨流出24.5億元人民幣，主要受季節性供應商款項支付、超50億元戰略性備貨投入影響。第二季度經營現金流回正，達46.2億元人民幣。

匯率波動造成外幣計價貨幣資產及負債產生約19.9億元人民幣損失；公司開展匯率風險管理業務實現約13.0億元人民幣收益。根據適用會計準則，該部分收益計入非經常性損益，而對應損失則納入兩項披露口徑的淨利潤核算範圍。

三大核心業務全線增長

消費電子業務營收1224.8億元人民幣，同比增長19.3%。立訊精密持續深化核心客戶合作，強化ODM以及端到端產品研發能力。依托聲學、光學、電氣系統、熱管理、磁學與精密結構件領域的綜合技術積累，公司業務範圍從零部件、模組進一步延伸至產品定義、系統開發以及規模化生產環節。業務重點覆蓋AI個人電腦、智能穿戴設備、AI眼鏡以及智能聲學產品。

通信與數據中心業務營收166.1億元人民幣，同比增長49.7%。公司打造覆蓋高速銅互聯、光互聯、熱管理、電源管理的一體化AI基礎設施產品矩陣。業務進展包括800G光產品實現量產；1.6T DAC、ACC、AEC產品批量出貨；液冷解決方案持續導入客戶；服務器DC-DC電源模塊規模化投產。同時，公司持續推進224G和448G銅互聯技術與下一代光架構的技術研發。

汽車電子業務營收323.9億元人民幣，同比大增274.1%，增長來源於內生業務增長、客戶項目量產以及萊尼(Leoni)並表貢獻。公司持續豐富產品矩陣，覆蓋連接器、線束、智能控制系統、智能底盤技術以及動力總成解決方案。高速連接器、後輪轉向產品已進入量產階段；智能座艙、高級駕駛輔助平台在多個整車項目穩步推進。萊尼的整合進度持續超出預期，進一步強化了公司全球客戶資源、工程研發實力與本地化交付能力。

全球化運營平台與未來展望

立訊精密業務遍佈五大洲、29個國家，擁有超100處生產基地。該網絡可保障本地化交付和客戶合作，提升供應鏈抗風險能力。公司垂直整合平台覆蓋精密零部件、功能模組和系統級產品；依托AI數字化工具，實現質量管理、預測性維護、生產排程與全球標準化運營。

展望2026年下半年，立訊精密將繼續配合消費電子產品發佈以及ODM/JDM項目落地；加快高速互聯、光模塊產品、液冷、電源管理相關業務商業化進程；拓展汽車領域客戶項目，持續釋放萊尼整合帶來的效益。

公司將繼續堅持審慎的資本配置策略，持續投入技術研發、製造產能與全球交付能力建設，推動業務實現可持續高質量增長。

關於立訊精密

立訊精密工業股份有限公司是全球精密智能製造解決方案服務商，業務覆蓋消費電子、通信與數據中心、汽車電子以及其他科技產業。公司可提供從產品定義、工藝開發，到新產品導入、規模化製造及全球交付的全鏈條服務。

摘要：

• 總收入達人民幣869.6億元，歸屬於母公司股東的利潤達人民幣17.2億元，同比增長160.3%；
• 核心產業運營質量穩步提升，產業運營利潤達人民幣36.9億元，同比增長17%；
• 全球化深度運營能力持續提升，海外收入達人民幣491.6億元，同比增長5.3%，佔集團總收入比重為56.5%；
• 科創投入達人民幣42億元，同比上升16.7%，創新藥進入密集獲批兌現期，7個創新藥品共20項適應症於境內外獲批上市；
• 堅持積極及審慎的流動性及負債管理，上半年完成非戰略非核心資產退出回流超人民幣120億元等值，總債務佔總資本比率降至55.7%；
• MSCI ESG評級升至最高級AAA，持續獲得國際權威機構認可。

香港2026年8月27日 /美通社/ -- 復星國際有限公司（香港聯交所股份代號：00656，簡稱「復星國際」）及其附屬公司（統稱「復星」或「集團」）今日公佈截至2026年6月30日止6個月之中期（簡稱「報告期」）業績。

2026年上半年，復星持續推進「瘦身健體、聚焦主業」戰略，在創新與全球化「雙引擎」驅動下，醫藥健康、保險金融、文旅消費等核心產業運營質量穩步提升、共振向上，推動盈利質量躍升。報告期內，集團總收入達人民幣869.6億元，在持續退出非戰略非核心資產的情況下，總體保持穩定；產業運營利潤達人民幣36.9億元，同比增長17%；歸屬於母公司股東的利潤達人民幣17.2億元，同比大幅增長160.3%。

報告期內，復星資產底盤保持穩健，旗下復星醫藥、豫園股份、復星葡萄牙保險、復星旅遊板塊合計收入達人民幣638.8億元，佔集團總收入比重為73.5%。海外收入達人民幣491.6億元，同比增長5.3%，佔總收入比重較2025年同期上升3個百分點至56.5%，充分驗證全球化成效。

與此同時，復星堅持積極審慎的流動性及負債管理，保持充足的流動性安全墊。報告期內，集團完成非戰略非核心資產退出回流超人民幣120億元等值。截至2026年6月30日，現金及銀行結餘及定期存款為人民幣612.14億元，較2025年末有所增加；總債務佔總資本比率為55.7%，較2025年末進一步下降。健康的負債比率及充裕的現金儲備，在加強集團抗禦風險能力的同時，也提高了把握投資機會的能力。

復星國際董事長郭廣昌表示：「過去幾年，復星堅定推進『瘦身健體、聚焦主業』，並完成了『晴天修屋頂』的系統性調整。今年上半年業績大幅修復，充分驗證了我們的戰略選擇及持續聚焦是對的。如今，復星已經重回增長軌道，未來我們會在這條軌道上發展得越來越快。」

堅持創新驅動，創新藥密集獲批提速價值兌現

2026年上半年，復星堅持創新驅動，全面擁抱AI應用，推動科創成果加速兌現與運營效率持續提升。報告期內，復星科創投入達到人民幣42億元，同比上升16.7%，「自主研發+投資孵化+生態合作」三位一體的全球創新體系持續發力，湧現出一批具有全球競爭力的創新成果。

圍繞解決未被滿足的臨床需求，健康板塊科創成果亮眼。報告期內，創新藥進入密集獲批兌現期，復星醫藥7個創新藥品共20項適應症於境內外獲批上市。其中，復邁寧（蘆沃美替尼片）獲批用於治療復發或難治性朗格漢斯細胞組織細胞增生症兒童及青少年患者，持續攻克罕見病治療空白。在神經退行性疾病領域，復星醫藥持續推進創新佈局：在已獲得中國境內及香港、澳門、約定的東南亞10國的開發、註冊、生產及獨家商業化權益基礎上，進一步獲得AR1001全球獨家選擇權，有權行使選擇權將許可區域拓展至全球包括美國、歐洲和日本等在內的關鍵市場，並作為該等區域的上市許可持有人；甘露特鈉膠囊於中國境內上市後確證性臨床試驗穩步推進，截至2026年7月31日已累計入組超1,000例；參股並孵化企業衡泰生物引進的HT001口服透腦NLRP3抑制劑（用於治療帕金森病）已在澳大利亞啓動I期臨床試驗。

作為健康板塊核心子公司，復星醫藥上半年實現營業收入人民幣203.77億元，其中，創新藥品收入同比增長13.84%，佔製藥業務收入比重提升至33.35%，成為增長核心引擎。

在生物創新藥領域，復星上半年不斷取得突破。復宏漢霖自主研發的H藥漢斯狀胃癌圍術期適應症獲中國藥監局批准，成為全球首個且唯一獲批該適應症的抗PD-1單抗，開創術後「去化療」新範式。創新管線核心資產HLX43作為潛在同類最優的廣譜抗腫瘤PD-L1 ADC，在非小細胞肺癌等多個實體瘤中已展現出「高效、低毒」的初步臨床療效，目前已開展十餘項單藥或聯合臨床研究，累計全球入組患者超1500例，持續驗證其在多種實體瘤中的廣譜治療潛力。

報告期內，復宏漢霖展現出強勁的內生增長動能與高質量造血能力，實現營收人民幣35.882億元，同比增長27.3%；淨利潤人民幣4.304億元，同比增長10.3%。

面對AI浪潮，復星圍繞核心業務及全球產業生態，瞄准「可落地的生產力」深耕AI應用，創造真實的產業價值。

復星醫藥完成「PharmAID醫藥數智體系V2.0」升級，形成四大板塊，推動產品管線從早期研發到臨床確證再到上市後市場全生命週期AI賦能。截至報告期末，復星醫藥已有超25個高價值AI項目投產，50餘項場景同步推進，覆蓋醫藥項目評估、靶點預測、分子優化等各業務線；已有2個AI輔助生成及結構化的新分子進入臨床前候選化合物階段。2026年3月，復宏漢霖自主研發的新一代rHuPH20輔料注射液，在中國獲批臨床，依託其「AI for Science」平台，原本18個月的酶分子設計週期，被大幅壓縮到了5個月。

除了製藥領域，AI已深度嵌入復星旗下文旅、保險、智造等業務。復星旅遊板塊加速落地「AI G.O」，並攜手頭部科技企業，圍繞AI賦能賓客體驗、雲端與AI原生平台轉型、全球增長三大方向展開深度合作。海南礦業結合AI技術帶來的資源需求，快速佈局螢石礦等上游核心資源。

全球化深度運營提質增效，境內外保險公司全線向好

依託在全球超過40個國家和地區的產業佈局和深度運營，復星全面推進「中國能力嫁接全球資源」戰略，將中國的製造能力、服務能力和創新紅利與全球市場深度結合。報告期內，集團海外收入達人民幣491.6億元，佔總收入比重達到56.5%。

2026年上半年，復星旗下企業的全球化能力持續增強，「出海」業務不斷取得重大突破。

在醫藥健康領域，復星醫藥境外業務收入同比增長16.45%，佔營業收入的比重提升至31.30%，同比提升3.11個百分點，收入結構持續優化。復宏漢霖H藥漢斯狀在歐盟獲批三項新增適應症，HLX11（帕妥珠單抗注射液）也在歐盟獲批上市，HLX14（地舒單抗注射液）兩個產品在加拿大獲批並實現商業化上市。截至目前，復宏漢霖已有10款產品於全球60多個國家及地區獲批上市，廣泛覆蓋亞洲、歐洲、拉丁美洲、北美洲和大洋洲，惠及逾110萬患者。復星健康持續推進國際化進程，積極拓展印尼、孟加拉、蒙古及港澳地區等市場，構建開放、穩定、專業的國際醫療協作網絡，此外，佛山復星禪誠醫院國際醫療中心大樓全新投用，構建全流程國際醫療服務閉環。

在消費及文旅領域，2026年上半年，豫園股份在中國港澳地區營業收入達人民幣5.32億元，同比增長285.83%；日本市場營業收入達人民幣3.06億元，同比增長6.09%。珠寶板塊海外拓展成果突出，老廟新增5 家港澳、海外及免稅門店，當前港澳、海外及免稅渠道總數已達15家。Club Med持續推進全球目的地佈局，Club Med地中海白日方舟•杭州龍塢度假村於2026年4月正式開村，Club Med地中海俱樂部南非海濱與Safari度假村於2026年7月起試營業。

在智造領域，海南礦業「馬里布谷尼鋰礦+海南星之海鋰鹽加工」一體化產業鏈穩定運行，成為公司業績增長的核心引擎，上半年完成三批次共7萬噸鋰精礦從非洲馬里運抵中國海南洋浦港。萬盛股份位於泰國基地的磷酸酯阻燃劑項目順利投產，填補了在海外製造環節的空白，為打造全球供應鏈注入新的韌性。

伴隨全球化戰略深入推進，2026年上半年復星旗下海內外保險公司業績全線向好。截至報告期末，復星葡萄牙保險在葡萄牙市場的整體份額達30.1%，國際業務佔合併總業務規模的26.7%，海外市場毛保費總額達歐元10.35億元。報告期內，儘管遭受葡萄牙多場風暴所帶來的損失，復星葡萄牙保險歸母淨利潤仍達歐元1.65億元，同比增長23.8%。

鼎睿再保險憑借優質客戶基礎、嚴謹核保紀律及全球化業務佈局，保持業績穩健。報告期內，再保險收入、毛保費同比分別增長25.0%及11.8%，並錄得稅後淨利潤美元8,970萬元。憑借穩健的財務實力及持續提升的市場地位，穆迪於2026年4月將鼎睿再保險評級由Baa1上調至A3，評級展望「穩定」。

境內方面，復星保德信人壽2026年上半年規模保費達人民幣83.8億元，同比增長52.2%；淨利潤人民幣7.8億元，同比增長270%，上半年淨利潤超過2025年全年水平。復星聯合健康保險收入同比增長36.2%，實現淨利潤人民幣5.72億元。

堅持商業向善，MSCI ESG評級升至最高級AAA

報告期內，復星在環境、社會及管治（ESG）領域持續獲得國際認可。MSCI ESG評級升至最高級AAA，再次成功入選標普全球《可持續發展年鑑2026》並在《可持續發展年鑑（中國版）2026》中名列最佳1%。此外，FTSE ESG評分持續領先全球行業及中國企業平均水平，並連續五年入選富時羅素社會責任指數（FTSE4Good Index Series）成份股。

復星持續為援非抗瘧貢獻「中國方案」。截至報告期末，復星醫藥自主研發的注射用青蒿琥酯全球累計供應量超4.6億支，累計救治超9,200萬重症瘧疾患者。以SPAQ-CO系列產品為核心藥物的「季節性瘧疾藥物預防項目」已惠及超3.3億名非洲兒童。

復星基金會發起的「鄉村醫生計劃」持續覆蓋16個省、市、自治區的78個項目縣，守護2.5萬名鄉村醫生，惠及300萬戶農村家庭、1,634萬農村人口。2026年上半年，為項目縣鄉村醫生投保團體意外險及重疾險累計超12,590份，為59個衛生室（院）進行智慧化升級，助力263位村醫考取鄉村全科執業助理醫師資格證；5月上線的2.0 版「AI村醫助手」服務成功率100%，村醫用戶滿意度達92%。

展望未來，郭廣昌表示：「上半年業績的修復不是偶然，而是復星堅守長期主義、持續深耕主業的必然結果。面向未來，我們將圍繞優勢產業，繼續推進創新驅動和全球化發展，沿著確定性的軌道，我們有信心逐步恢復人民幣百億利潤規模。」

G50滬渝高速公路（上海段）改擴建工程動工

宣派中期股息每股42港仙回饋股東支持，派息率高達43.2%

香港2026年8月27日 /美通社/ -- 上海實業控股有限公司（「上實控股」或「公司」，連同其附屬公司統稱「集團」；香港聯交所編號363）公佈截至二零二六年六月三十日止未經審核之中期業績。營業額為88.05億港元，同比下跌7.1%，主要由於本期間房地產交樓結轉物業銷售減少。公司擁有人應佔溢利錄得10.58億港元，同比上升1.6%，主要因為去年同期房地產業務有大額存貨跌價計提撥備。董事會宣派中期股息每股42港仙，派息率達43.2%，回饋股東長期支持。

二零二六年中期業績摘要：

業務分部收入及利潤摘要：

二零二六年上半年，本集團堅持「穩中求進、守正創新」的發展基調，持續優化資產與業務佈局，在確保三大主營業務穩健運營的同時，重點推進綠色健康產業部署，全力推動業務高質量發展。

截至二零二六年六月三十日止六個月，本集團未經審核營業額為88.05億港元，較去年同期下跌7.1%，收入下跌主要是由於本期間房地產交樓結轉物業銷售減少。股東應佔溢利錄得10.58億港元，同比上升1.6%，主要因為去年同期房地產業務有大額存貨跌價計提撥備。

本期間基建環保業務盈利同比上升1.9%至9.51億港元，佔集團業務淨利潤約114.2%。收費公路業務利潤同比上升11.1%至6.09億港元，繼續為本集團帶來穩定的現金流。旗下G50滬渝高速公路拓寬改建工程正式動工，將原有雙向四至六車道升級為雙向八車道，將大幅提升道路通行容量。項目採用「邊運營、邊施工」的模式，保障跨區域通行不間斷。在污水處理領域，上實環境採取「存量優化+外延擴張」的雙輪驅動策略積極拓展市場，完成收購鞍山清暢水務及鞍山清朗水務100%股權，進一步鞏固本集團於中國水務及環保產業的領先地位。2026年6月18日，本公司之間接全資附屬公司上海躋沄與數家企業成立合夥企業，合夥企業之目標基金規模為人民幣10億元，初始出資額約為人民幣5.06億元，目標投資於水務環保、電力新能源、綠色低碳、智慧化產業升級和先進裝備製造等領域，進一步拓展環境可持續發展產業。 

房地產業務本期間錄得虧損4.11億港元，較去年同期虧損減少約11.6%，佔集團業務淨利潤為負49.4%。

面對消費市場下行壓力持續加大與行業監管日趨嚴格的雙重挑戰，消費品業務本期間盈利貢獻為2.93億港元，同比下降27.3%，佔集團業務淨利潤35.2%。旗下南洋煙草和永發印務通過主動調整業務結構、降本增效、積極拓展新業務和市場等舉措，保持了穩健的經營態勢。

業務摘要：

基建環保

• 本集團旗下三條收費公路，上半年總體車流量同比增長1.0%，通行費收入同比增加4.9%至10.7億港元，集團所佔淨利潤同比增加11.1%至6.09億港元，為集團帶來穩定的現金流。
• 旗下上實環境（BHK SGX，807 HKSE）二零二六年上半年營業額錄得人民幣31.85億元，同比增加0.2%，股東應佔溢利為人民幣3.25億元，同比減少5.5%。期內上實環境持續提升核心業務競爭力，同步優化融資及資本結構，財務費用同比大幅下降18.4%至人民幣 2.86 億元。上半年實現經營活動現金流淨流入人民幣5.47億元。截至2026年6月30日，資產負債率由去年同期的63.8%進一步優化至61.8%，流動比率由114%提升至147%，現金及現金等價物達人民幣28.46億元。
• 上實環境上半年新增污水處理規模每日230,000噸，完成大連旅順污水處理廠及再生水管道建設項目的交割，合計污水處理項目達每日60,000噸；上海杭州灣工業廢水處理廠項目投入運營，設計處理規模每日12,000噸；新中標寧波污水處理廠項目，設計處理規模每日70,000噸。
• 中環水務期內實現營業收入10.31億港元，同比增加5.2%。淨利潤1.73億港元，同比增加43.9%。期內新增/新簽項目共5個，涉及水處理規模每日163,600噸。
• 截至二零二六年六月底，上實新能源及其控股公司持有的光伏電站資產規模達740兆瓦，期內15個光伏發電項目完成上網電量約4.16億千瓦時，同比下降11.9%，主要是受到持續限電的影響。

房地產

• 旗下上實發展（600748 SSE）期內錄得營業額人民幣10.16億元，同比下跌17.6%，淨虧損人民幣2.58億元，虧損同比減少65.8%，主因是去年同期有大額存貨跌價計提撥備。期內簽約金額為人民幣2.11億元，半年租金收入約人民幣1.73億元。
• 旗下上實城開（563 HKSE）期內錄得營業額12.72億港元，同比下跌30.4%，主要由於多個項目交付之銷售額較去年同期下降。本期間股東應佔虧損為4.14億港元，較去年同期虧損減少15.8%。期內實現簽約金額為人民幣12.90億元，在建項目5個。半年租金收入約4.18億港元，來自租金、物業管理，以及酒店業務的收入持續為公司提供穩定的收入來源。

消費品

• 受市場下行壓力持續加大及行業監管日趨嚴格的雙重挑戰，南洋煙草上半年錄得營業收入為11.14億港元，同比減少12.5%，淨利潤2.50億港元，同比減少25.8%。
• 南洋煙草積極應對，通過引入經銷煙新品，本港市場銷售額基本保持平穩，澳門市場銷售額顯著增長。免稅市場今年上半年表現亮眼，整體銷售額超越去年同期。中專市場成功實現三款新品的置換，並於短時間內落實了上半年計劃量的生產發運工作。
• 永發印務期內收入6.71億港元，同比下降11.6%；期內實現淨利潤4,360萬港元，較去年同期減少37.7%。受益於核心客戶訂單量增加，藥包業務錄得雙位數增長，成為本期收入增長的主要驅動力。模塑業務方面，受主要客戶降價和芯片短缺等因素影響，收入呈現階段性波動。

上實控股董事長冷偉青表示：「下半年，本集團將秉持穩健經營理念的同時，緊扣『聚力奮鬥』主線，堅定聚焦環境健康核心賽道，全面提升企業競爭力。基建環保業務方面，上實環境將緊抓『十五五』政策機遇與市場機會，積極拓展優勢項目與戰略性併購，持續擴大市場份額，鞏固在中國水務及環保產業的領先地位。收費公路有序推進改擴建工作和項目工程，提升道路及設施狀況，確保運營安全平穩。房地產業務方面，將密切關注政策動向與市場演變，積極把握核心城市與改善型需求的結構性機遇，全力提升業務質效。南洋煙草將持續深耕核心業務，加快數字化轉型步伐，推動產能與設備升級，提升核心產業競爭力。永發印務將堅定推進『綠色化、智能化、國際化、品牌化』四輪驅動戰略，深耕藥包及高附加值業務，增強整體盈利能力及抗風險能力。總體來說，集團將在確保各項主營業務穩健運營的同時，推動邁向更高質量的發展，為股東創造更大價值。」

關於上實控股

上海實業控股有限公司（簡稱：上實控股，香港聯交所編號363）是上實集團在海外最大的綜合性企業，作為上實集團的旗艦企業，我們得以把握在國內投資機會，體現立足滬港、聯動國際的優勢。經過三十年的發展，上實控股已成為一家以基建環保（包括收費公路、污水處理及固廢處理等環保相關業務）、房地產和消費品（包括南洋煙草和永發印務）三大核心業務為主的綜合性企業。上實控股將不斷提升企業管治水平，致力為股東創造更大價值。

如需進一步瞭解上實控股，請瀏覽公司網站www.sihl.com.hk。

Turnover of Digital Energy Services and International Business Both Doubled

Data Center Orders Surge 153% as Computing Power and Electric Power Coordination Leads a New Chapter in Digital Energy in the AI Era

Financial Highlights

• Turnover of RMB5.39 billion (same below), representing a year-on-year ("YoY") increase of 23%
• Smart Grid Solutions business recorded a turnover of RMB1.99 billion, representing a YoY increase of 6%
• Digital Energy Services business recorded a turnover of RMB2.39 billion, representing a YoY increase of 98%
• International Markets business recorded a turnover of RMB2.39 billion, representing a YoY surge of 92%
• Net profit attributable to owners of the Company was RMB446 million, representing a YoY increase of 1%

HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Wasion Holdings Limited ("Wasion" or the "Group"; stock code: 3393.HK), China's leading provider of energy measurement equipment and energy-saving solutions, today announced its unaudited consolidated results for the six months ended 30 June 2026 ("the period under review").

During the period under review, the Group recorded a turnover of RMB5.39 billion, representing a YoY increase of 23%; gross profit amounted to RMB1.69 billion, representing a YoY increase of 9%; overall gross profit margin was 31.28%; and net profit attributable to owners of the Company amounted to RMB446 million, representing a YoY increase of 1%.

Energy Efficiency Holds Ample Contracts on Hand, Digital Energy Orders Up 101%

The Smart Grid Solutions (formerly known as "Power Advanced Metering Infrastructure") business recorded a turnover of RMB1.99 billion, representing a YoY increase of 6%. During the period under review, in the centralized tenders organized by State Grid, the Group's subsidiary, Wasion Group Limited, secured contracts worth RMB309 million by virtue of its capabilities, ranking first in the industry in terms of market share; in the Inner Mongolia local power company's centralized procurement, it won contracts worth RMB84 million, also ranking first in the industry. In the non-power grid sector, leveraging its years of technological expertise in the R&D and manufacturing of power meters, the Group completed domestic trading contracts exceeding RMB300 million, achieving rapid growth in related business and contract value; underpinned by its R&D advantages in base station photovoltaic integration and power supply products, the communications business maintained a stable market share and continued to serve as a steady source of revenue for the Group.

The AI-Integrated Energy Efficiency Solutions (formerly known as "Communication and Fluid Advanced Metering Infrastructure") business recorded a turnover of RMB1.01 billion, representing a YoY decrease of 22%, with the total value of signed contracts on hand reaching RMB3.82 billion and the total value of newly signed contracts reaching RMB1.31 billion, providing strong support for the Group's future business development. During the period under review, according to recent tender results from State Grid and Southern Grid, the Group's core products ranked among the top, firmly maintaining a leading position in the industry; as a Vice-Chair Unit of the Power Industry AI Alliance, the Group participated deeply in the formulation of industry AI application standards. In the first half of the year, the Group achieved outstanding results in transformer area governance and transmission line online monitoring of the distribution network digitalization business, with cumulative contract awards exceeding RMB300 million, firmly maintaining a leading industry position. The Group's global expansion entered a harvest period, with its Indonesian factory continuing to serve as a core production base for the Southeast Asian market; its technology center in Saudi Arabia was positioned as a technology service and project hub for the Middle East region; and the newly established subsidiary in Morocco further refined the operational system in the Middle East region. During the period under review, overseas mass shipments of communication modules exceeded RMB50 million in value, representing a more than 18-fold YoY increase.

Smart Distribution Network Gains Market Share, Data Center and Energy Storage Make Significant Progress

During the period under review, the Digital Energy Services (formerly known as "Advanced Distribution Operations") business recorded a turnover of RMB2.39 billion, representing a significant YoY increase of 98%; orders secured amounted to RMB4.47 billion, representing a surge of 101% over the same period last year. Among these, the value of bids won for smart distribution networks exceeded RMB2.15 billion, representing a substantial increase of 96% over the same period last year, primarily attributable to the rapid growth of overseas distribution network equipment business; benefiting from the accelerated demand for data center construction driven by AI and the rapid development of overseas data center business, the value of bids won in relation to data centers exceeded RMB1.89 billion, representing a surge of 153% over the same period last year; orders related to new energy storage amounted to over RMB430 million, representing an increase of 11% over the same period last year.

During the period under review, the Group's core product categories in the smart distribution network sector, such as primary and secondary integration pole-mounted circuit breakers and transformer packages, recorded impressive growth, with brand value and market share steadily rising. In the data center business, while consolidating its position with the three major telecommunications operators in the domestic market, the Group deepened cooperation with leading internet enterprises and became a strategic partner to these companies, while completing benchmark projects for multiple third-party data centers; in international markets, leveraging core customer resources, the Group successfully expanded into several markets including Malaysia, Thailand and Indonesia, and was shortlisted in the supplier system of major overseas AIDC service providers. As for the new energy storage business, the Group focused on the charging and swapping segment in the domestic market and launched lithium-ion battery-swapping cabinet projects in multiple provinces, while continuing to deepen cooperation with leading telecommunications service providers; in international markets, the Group has successfully established a presence in North America, Australia, Europe and Africa, building a standardized and replicable development model for multiple scenarios.

International Orders More Than Double, with Broad-based Growth Across Multiple Markets

In the first half of 2026, the Group secured overseas orders worth approximately RMB4.44 billion, representing a YoY increase of 108%. During the period under review, the Group fully capitalized on market opportunities arising from the global energy transition and the accelerated modernization of power grids in various countries. With its power business as the driving force and leveraging its core competitive advantage in integrated "hardware + software + service" solutions, the Group continued to deepen its market presence across regions, achieving breakthrough growth in its international business.

In the South American market, the Group took Brazil as its core strategic pivot, with business coverage extending across South and Central America. Among these, the bid value for the Brazilian recloser project approached RMB260 million, driving a remarkable YoY surge of 287% in the overall contract value of the South American market. Driven by local grid assessment policies in Brazil, reclosers have shifted from optional purchases to rigid demand and established an exclusive supply barrier, becoming the core growth engine for the market; the Group's local factory achieved localized production, effectively avoiding the risks of cross-border tariffs and logistics delays. In the North American market, the Group took Mexico as its strategic core, with newly signed contracts increasing by 43% YoY; the value of bids won for power meters reached RMB690 million, while contracts and deliveries for reclosers and transformers both hit record highs, with high-margin power distribution products becoming the region's primary growth driver; new businesses including energy storage, water utility services and smart city solutions achieved breakthrough implementations during the period, while the Mexico factory established core competitive advantages in compliance, cost and delivery.

In the Asian market, the Group identified the Middle East and Southeast Asia as key markets, with newly signed contract value increasing by 578% YoY. Large-scale framework orders were secured in a concentrated manner, with ample order reserves for channel business, while the pulling effect of EPC new products and major projects was significant, with relevant orders expected to be delivered gradually over the next year. The channel foundation in the Middle East remained solid, while market shares in mature markets such as Malaysia, Singapore and Indonesia steadily increased; first orders were also achieved in emerging markets such as Myanmar and Fiji, with regional coverage and market penetration depth expanding simultaneously. In the African market, the Group relied on dual production bases in Tanzania and South Africa as core growth drivers, with newly signed contracts increasing by 52% YoY; in the South African market, the Group was successfully shortlisted by the national power utility, with local factory production capacity and market adaptability continuously improving; the emerging market in Kenya achieved initial results, while the Group is advancing projects in Côte d'Ivoire, Nigeria, Uganda and other West African and Central-East African regions in phases, with regional market coverage continuing to expand.

Domestic Focus on Digital & Intelligent Upgrades, International Emphasis on Localized Production, and Computing-Power-Electric-Power Coordination Driving Data Center and Energy Storage Globalization

Looking ahead, in the domestic market, as fixed-asset investment in the national power grid during the 15th Five-Year Plan period is expected to exceed RMB5 trillion, power grid upgrades and equipment renewal will bring a new round of opportunities for the Group. The Group will closely follow policy directions, seize the opportunities arising from the growth in the scale of centralized procurement of metering equipment, focus on infrastructure, new energy and key industry projects, and consolidate core markets including major customers and operators. At the technological level, leveraging its deep expertise in the power IoT sector, the Group will follow the development trend of "sensing-computing-communication" integrated chips and digital twin power grids, drive the transition of power grids from digitalization toward intelligent digitalization, and continuously refine its four business pillars of smart power grids, smart water management, AI-driven intelligent computing, and satellite communications. In international markets, the Group will comprehensively deepen its regional market presence: in the Americas, it will take Brazil as its core strategic pivot to deepen its presence in mature South American markets, while leveraging its manufacturing base in Mexico to penetrate incremental markets in North America; in Europe, it will take Hungary as its foundation and focus on developing high-end markets in Germany, Turkey and Northwest Europe; in Asia, it will promote the strategic shift from "broad coverage" to "deep localized rooting"; and in Africa, it will rely on the dual production bases in Tanzania and South Africa as growth drivers to vigorously expand into high-potential markets in West Africa and Central-East Africa. At the same time, the Group will seize the strategic opportunity of "computing power and electric power coordination", deepen the global layout of its data center business, leverage power modules and IT prefabricated cabins to drive rapid business growth, accelerate the R&D and mass production of new products such as liquid cooling CDUs, HVDC and solid-state transformers, and build an integrated "equipment supply + electromechanical general contracting" service system; as for the new energy storage business, the Group will focus on the charging and swapping segment in the domestic market and launch standardized energy storage products tailored to diverse scenarios according to the needs of different overseas regions, continuously consolidating its market and technological competitiveness and gradually building comprehensive service capabilities in smart energy and intelligent computing.

Mr. Ji Wei, Chairman of the Group, said: "During the period under review, the Group's core business orders delivered outstanding performance, with both the Digital Energy Services business and overseas market orders doubling, while the data center-related business recorded particularly strong growth of more than double, fully demonstrating the effectiveness of the Group's strategic layout in the field of computing power and electric power coordination. Facing the historic opportunity arising from the deep integration of the global energy transition and artificial intelligence technologies, the Group, leveraging its core strategy of 'IoT + Chips + AI', continued to consolidate its core technological innovation and leading market position, while its international business achieved breakthrough growth and its localized manufacturing and delivery system continued to improve. Meanwhile, the Group seized the development opportunities of the computing power economy, successfully expanded its data center business into multiple emerging overseas markets, and established a presence for its new energy storage products in regions including North America, Australia, Europe and Africa. Looking ahead, we will remain firmly committed to driving development through technological innovation and strive to become a leading Digital Energy Services provider in the AI era, creating sustainable value for our shareholders and society."

About Wasion Holdings Limited

Wasion Holdings is the leading provider of comprehensive smart metering, smart distribution and utilisation, and energy efficiency management solutions in the PRC. The Group focuses on delivering integrated solutions that span R&D, production, and sales, serving utility companies in the electricity, water, gas, and heat sectors, as well as major industrial and commercial users. Its business primarily encompasses three key areas: (I) Smart Grid Solutions, which includes a full range of electricity, water, gas, and heat metering products and systems, commanding over 20% share in the domestic high-end market; (II) Digital Energy Services, offering solutions for smart distribution grids, data centres, and new energy storage; and (III) AI-Integrated Energy Efficiency Solutions, provided through its subsidiary Wasion Information (listed on the STAR Market and recognised as a National Specialised and Sophisticated "Little Giant" Enterprise), integrating IoT, chips, and artificial intelligence technologies. Having cultivated overseas markets for over two decades, the Group has established production lines in Tanzania, Brazil, Mexico, Hungary, Indonesia, Saudi Arabia, and South Africa, achieving localised operations. It is actively expanding into areas such as power distribution, energy storage, photovoltaics, and battery swapping to advance its internationalisation strategy. Upholding its core value of "Sincerity Brings Excellence, Mutual Benefit Brings Prosperity", the Group strives to become a leading global supplier in the international smart metering sector and a world-renowned brand.

For more information, please visit: http://ir.wasion.com/tc/index.php 

OpenAI has launched its in-house Jalapeno chip, saying its performance in testing surpasses NVIDIA Corporation (NVDA.US)'s existing product lineup. NVIDIA CEO Jensen Huang appeared unfazed by the challenge from Jalapeno, saying that even as customers develop their own chips, he remains confident in NVIDIA Corporation's technology and its ability to supply the industry.

Asked about OpenAI developing chips that could challenge NVIDIA Corporation while also receiving billions of USD in investment from the company, Huang said he does not mind competition. He noted that the AI chip industry is full of uncertainty, with many projects being launched while many others are cancelled.
~

AASTOCKS Financial News
Website: www.aastocks.com

This morning (27th), the HSI opened up 121 pts before turning south, once fading 152 pts to a trough of 25,500. The index closed at 25,565, down 87 pts or 0.34%, with market turnover at HKD233.5 billion. The HSCEI finished at 8,490, down 43 pts or 0.51%. The HSTECH ended at 4,620, down 5 pts or 0.13%.

Among major techs, BIDU-SW (09888.HK) will convert to dual primary listing status on the Stock Exchange starting next Tuesday, with its share price mounting 5.34% for the day. TENCENT (00700.HK) added 0.54%; MEITUAN-W (03690.HK) fell 0.7%; and NTES (09999.HK) dropped more than 1%. XIAOMI-W (01810.HK) slid 3.44%, making it the worst-performing blue chip of the day.

NVIDIA Corporation (NVDA.US) reported quarterly results that beat expectations, with shares soaring nearly 5% in after-hours trading. Hong Kong-listed chip and AI hardware stocks followed higher. HUA HONG GRACE (01347.HK), which will become an HSI constituent, elevated 4.51% after logging a fourfold spike in interim profit. SMIC (00981.HK) jumped up 2.3%; ILUVATAR COREX (09903.HK) rallied 10.54%; MONTAGE TECH (06809.HK) proliferated 12.3%; and GIGADEVICE (03986.HK) shot up 7.05%.

Among AI large model stocks, MINIMAX-W (00100.HK) swelled 3.83% after Citi raised its TP following results, saying the company's annualized revenue in August exceeded USD800 million and beat expectations. Z.AI (02513.HK) jumped up 12.62% after its GLM-5.3-Flash model was launched and open-sourced.

Printed circuit board (PCB) and copper clad laminate (CCL) stocks ascended this morning alongside A-share peers. KB LAMINATES (01888.HK) mushroomed 10.51%; KINGBOARD HLDG (00148.HK) advanced 7.2%; CFMEE (09630.HK) ballooned 4.02%; HANS CNC (03200.HK) elevated 6.07%; and VGT (02476.HK) leapfrogged 6.93%.

Optical communication concept stocks also fared well. ZJ INNOLIGHT (03308.HK) climbed 3.05%; YOFC (06869.HK) rebounded sharply by 10.31%; CREALIGHTS (01191.HK) skyrocketed 5.49%; and CIG (06166.HK) escalated 5.22%.
~

AASTOCKS Financial News
Website: www.aastocks.com